Douglas Buxton, MD
Ophthalmology · New York, NYNPI 1013095272
Payments from drug & device makers
Across 838 payments — averaging $61.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$18K
- Ocular Therapeutix, Inc.$5K
- Mallinckrodt Hospital Products Inc.$5K
- Alcon$4K
- AbbVie$2K
- Glaukos Corporation$2K
- plus $15K from 32 others
What the payments were for
- Consulting fees$4,7759%
- Speaking & faculty fees$19,44338%
- Travel & lodging$3,3307%
- Food & beverage$23,17945%
- Education$4381%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$20,518
- DEXTENZA$5,075
- iStent Trabecular Micro-Bypass Stent System$1,000
- OMNI(R) SURGICAL SYSTEM (US)$656
- XIIDRA$520
- DEXYCU$411
- VYZULTA$351
- Clareon$299
- XDEMVY$269
- Tecnis IOL$268
- VEVYE$259
- OMNI$222
- Centurion$150
- Hydrus Microstent$146
- NGENUITY$135
- INVELTYS$127
- EYSUVIS$127
- ACTIVEFOCUS$127
- AcrySof$127
- OMIDRIA$125
How this compares
$51,185 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 326 | $333,526 |
| LumiganBimatoprost | 246 | $129,181 |
| CequaCyclosporine | 132 | $116,695 |
| XiidraLifitegrast | 90 | $95,161 |
| VyzultaLatanoprostene Bunod | 142 | $54,639 |
| TyrvayaVarenicline Tartrate | 65 | $44,940 |
| CombiganBrimonidine Tartrate/Timolol | 94 | $37,565 |
| MieboPerfluorohexyloctane/Pf | 39 | $30,039 |
| RocklatanNetarsudil Mesylat/Latanoprost | 55 | $27,119 |
| RhopressaNetarsudil Mesylate | 39 | $20,280 |
| LotemaxLoteprednol Etabonate | 36 | $19,684 |
| ProlensaBromfenac Sodium | 58 | $19,601 |
| EysuvisLoteprednol Etabonate | 35 | $16,893 |
| Lotemax SmLoteprednol Etabonate | 43 | $13,504 |
| Alphagan PBrimonidine Tartrate | 36 | $12,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,779 | $512,977702 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $1,196 | $179,839271 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,568 | $116,695132 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Prolensa, Lotemax Sm, Loteprednol Etabonate, Besivance | $939 | $69,799225 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $378 | $47,39994 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $976 | $44,94065 claims |
| Eyevance Pharmaceuticals LLCFlarex, Tobradex St, Zerviate | $231 | $17,42992 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $748 | $16,89335 claims |
| AlconSimbrinza, Azopt | $3,977 | $10,37539 claims |
| NovartisIlevro | $366 | $8,86124 claims |
| Thea Pharma Inc.Iyuzeh | $234 | $6,05413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.